Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Bristol-Myers Squibb
7 Hills Pharma, LLC
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
West China Hospital
Pfizer
National Institutes of Health Clinical Center (CC)
State University of New York at Buffalo
Aulos Bioscience, Inc.
Bristol-Myers Squibb
3D Medicines
BeOne Medicines
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
GI Innovation, Inc.
AstraZeneca
Mayo Clinic
Jonsson Comprehensive Cancer Center
Genmab
Oncorena AB
Neonc Technologies, Inc.
Roswell Park Cancer Institute
Merck Sharp & Dohme LLC
Genenta Science
University of California, Davis
Beth Israel Deaconess Medical Center
Merck Sharp & Dohme LLC
University of Texas Southwestern Medical Center
M.D. Anderson Cancer Center
University of California, San Diego
Ocellaris Pharma, Inc.
iOmx Therapeutics AG
Inhibrx Biosciences, Inc
Bristol-Myers Squibb
Regeneron Pharmaceuticals
University of Iowa
CRISPR Therapeutics
NiKang Therapeutics, Inc.
Regeneron Pharmaceuticals
University of Pittsburgh
Fox Chase Cancer Center
Dragonfly Therapeutics
ITM Oncologics GmbH
Arsenal Biosciences, Inc.
Scancell Ltd
Vyriad, Inc.
GI Innovation, Inc.
A2 Biotherapeutics Inc.